Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

This is a single-arm, open-label, phase 1b study evaluating the safety and feasibility of using talquetamab as bridging therapy prior to cilta-cel in patients with relapsed and refractory multiple myeloma (RRMM).

NCT Number	NCT07093554
Lead Sponsor	Medical College of Wisconsin
Conditions	Relapse Multiple Myeloma, Refractory Multiple Myeloma
Enrollment	31 participants
Start Date	2025-12-02
Primary Completion	2027-07-01 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-05